TRANSCATHETER AORTIC VALVE REPLACEMENT MARKET Challenges and Opportunities

The high cost of transcatheter aortic valve replacement devices poses a major challenge for the global transcatheter aortic valve replacement market growth. TAVR devices are significantly more expensive than standard open-heart surgical aortic valve replacements (SAVR). The estimated average cost of TAVR procedure in the U.S. ranges between US$ 60,000 and US$ 100,000 compared to around US$ 30,000 for SAVR. While TAVR is considered cost-effective for inoperable patients considering alternative treatment costs, the higher costs limit access to therapy for many patients.

Market Opportunity - Expansion of TAVR indications to include lower-risk patient populations

The expansion of TAVR indications to include lower-risk patient populations presents a major opportunity for long-term growth of the global transcatheter aortic valve replacement market. Currently, transcatheter aortic valve replacement is only approved for inoperable and high-risk patients in most countries. However, recent clinical evidence like SURTAVI trial has demonstrated the non-inferiority and in some cases superiority of transcatheter aortic valve replacement over standard open-heart surgical aortic valve replacements (SAVR) in intermediate risk patients. Expanding approved indications to include lower surgical risk groups will immensely increase the size of addressable patient population worldwide.